Investors Are Watching: Bovie Medical Corporation (NYSEMKT:BVX), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Pharmacyclics Inc. (NASDAQ:PCYC), Geeknet, Inc. (NASDAQ:GKNT), ReneSola Ltd. (NYSE:SOL)

Bovie Medical Corporation (NYSEMKT:BVX) shares remains unchanged in last trading session and ended the day at $2.89. BVX Gross Margin is 32.50% and its return on assets is -93.20%. Bovie Medical Corporation (NYSEMKT:BVX) quarterly performance is -14.50%. On May 26, Bovie Medical Corporation (NYSE:BVX), announced that it has hired Mark Charbonneau as J-Plasma® Product Development Manager. Prior to joining Bovie, Mark was an engineering manager for Centrix and senior manufacturing engineer for Ventripoint Diagnostics.

On 29 May, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares moved down -1.22% and was closed at $238.77. VRX EPS growth in last 5 year was 19.20%. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) year to date (YTD) performance is 66.84%. On May 27, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan® 550 mg for the treatment of IBS-D in adults. The FDA approval of Xifaxan 550 mg is based on data from three phase 3 studies, TARGET 1, TARGET 2 and TARGET 3. Xifaxan 550 mg was studied in over 3,000 patients and demonstrated the efficacy and safety of repeat treatment following completion of a two-week course of treatment. A full course of Xifaxan 550 mg for IBS-D is available in a convenient 2 week pack of 42 pills.

Pharmacyclics Inc. (NASDAQ:PCYC) belongs to Healthcare sector. Its net profit margin is 8.80% and weekly performance is 2.28%. On last trading day company shares ended up $261.25. Pharmacyclics Inc. (NASDAQ:PCYC) distance from 50-day simple moving average (SMA50) is 1.74%. Pharmacyclics LLC (NASDAQ:PCYC) reported interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease, or cGVHD, who were either refractory to steroid treatment or were steroid-dependent. The company said, in a preliminary analysis, data show all five evaluable patients who had received at least three months of ibrutinib achieved a partial response, and two patients who were evaluable at six months maintained a partial response.

Geeknet, Inc. (NASDAQ:GKNT) shares increased 5.01% in last trading session and ended the day at $19.90. GKNT Gross Margin is 17.60% and its return on assets is -12.60%. Geeknet, Inc. (NASDAQ:GKNT) quarterly performance is 179.49%. Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Geeknet, Inc. (NASDAQ:GKNT) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Hot Topic, Inc. (“Hot Topic”).

ReneSola Ltd. (NYSE:SOL) shares moved down -3.31% in last trading session and ended the day at $1.46. SOL Gross Margin is 13.40% and its return on assets is -1.90%. ReneSola Ltd. (NYSE:SOL) quarterly performance is 9.77%. ReneSola Ltd. (NYSE:SOL) announced that it will report its unaudited financial results for the first quarter ended March 31, 2015 before the U.S. markets open on June 2, 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *